1. Educational Experience
In 1994, graduated from China Pharmaceutical University.
In 1997, received master's degree from China Pharmaceutical University.
In 2003, received doctor's degree from China Pharmaceutical University.
In 2001, studied at University of Otago in New Zealand.
From 2007 to 2010, conducted postdoctoral research at Nanjing University.
2. Working Experience
Has been teaching at China Pharmaceutical University since 1997.
From January 2013 to June 2013,was secondment to the Department of National Drug Evaluation Center.
From August 2013 to August 2014,worked in BioBAY, Suzhou Industrial Park.
Since January 2018,has served as the Executive Vice President of Innovative Pharmaceutical Research Institute of China Pharmaceutical University (Hangzhou).
Nano-drug delivery system,sustained-release formulations.
1. Research Projects
(1) National Natural Science Foundation of China, Study on synchronous Drug delivery system of baicalein and photothermal chemotherapy based on reactive oxygen species, 2018-2021, No.81773908.
(2) National Natural Science Foundation of China, Study on liposomes of traditional Chinese medicine based on glycyrrhetinic acid receptor actively targeting liver parenchyma cells, 2011-2013, No.81073055.
(3) Major new drug project of the 12th five-year Plan, Preclinical study of baicalein tablets, a new kind of antiviral drug of traditional Chinese medicine, 2012-2015, 2012ZX09102112.
(4) Social Development Project of Jiangsu Province, Development of Scutellaria tablets, 2010-2012，BE2010725.
2. Academic Awards
(1) In 2011, was awarded the third-level training object title of the fourth 333 High-level Talent Training Project in Jiangsu Province, and the management period was from 2011 to 2015.
(2) In 2012, was selected into the 2011 annual New Century Outstanding Talents Support Plan.
3. Representative Research Achievements
(1) Published a paper named Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia，developed a biomimetic nanosystem (DR@PLip) based on platelet membrane (PM) coating and doxorubicin (DOX)/ginsenoside (Rg3) co-loading to potentiate the local-to-systemic chemoimmunotherapy for AML.The participation of Rg3 was proved to enhance the tumor sensitivity to DOX, thus initiating the anti-tumor immune activation and effectively combating the leukemia cells hiding in the bone marrow.
(2) Published a paper named Low molecular weight heparin modified bone targeting liposomes fororthotopic osteosarcoma and breast cancer bone metastatic tumors.Utilized the alendronate (ALN) and low molecular weight heparin (LMWH) modified liposomes to deliver the antitumor drug doxorubicin (DOX), where traditionally-believed non-active drug carrier, targeting moiety could also exhibit biological functions and realize anti-tumor and anti-metastasis efficiency synergistically with the antitumor drug. Besides, both the orthotopic osteosarcoma model and bone metastasis cancer model were adopted to evaluate the in vivo efficacy.
1. Chen, M.; Qiao, Y.; Cao, J.; Ta, L.; Ci, T.; Ke, X. Biomimetic doxorubicin/ ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia. J Nanobiotechnology 2022, 20 (1), 273. IF:9.7
2. Dai, J.; Chen, M.; Xu, D.; Li, H.; Qiao, Y.; Ke, X.; Ci, T. Self-assembly delivery system based on small-molecule camptothecin prodrug for treatment of colorectal carcinoma. Nanomedicine (Lond) 2021, 16 (5), 355-372. IF:6.1
3. Wu, H.; Luo, Y.; Xu, D.; Ke, X.; Ci, T. Low molecular weight heparin modified bone targeting liposomes for orthotopic osteosarcoma and breast cancer bone metastatic tumors. Int J Biol Macromol 2020, 164, 2583-2597. IF:7.0
4. Cao, D.; Zhang, X.; Akabar, M. D.; Luo, Y.; Wu, H.; Ke, X.; Ci, T. Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. Artif Cells Nanomed Biotechnol 2019, 47 (1), 181-191. IF:3.3
5. Xia, Y.; Yuan, M.; Chen, M.; Li, J.; Ci, T.; Ke, X. Liquid jet breakup: A new method for the preparation of poly lactic-co-glycolic acid microspheres. Eur J Pharm Biopharm 2019, 137, 140-147. IF:4.6
6. Wang, J.; Meng, F.; Kim, B. K.; Ke, X.; Yeo, Y. In-vitro and in-vivo difference in gene delivery by lithocholic acid-polyethyleneimine conjugate. Biomaterials 2019, 217. 119296. IF:10.3
7. Sun, H.; Cao, D.; Liu, Y.; Wang, H.; Ke, X.; Ci, T. Low molecular weight heparin-based reduction-sensitive nanoparticles for antitumor and anti-metastasis of orthotopic breast cancer. Biomater Sci 2018, 6 (8), 2172-2188. IF:5.3
8. Ci, T.; Yuan, L.; Bao, X.; Hou, Y.; Wu, H.; Sun, H.; Cao, D.; Ke, X. Development and anti-Candida evaluation of the vaginal delivery system of amphotericin B nanosuspension-loaded thermogel. J Drug Target 2018, 26 (9), 829-839. IF:3.3
9. Chen, Y.; Li, H.; Deng, Y.; Sun, H.; Ke, X.; Ci, T. Near-infrared light triggered drug delivery system for higher efficacy of combined chemo-photothermal treatment. Acta Biomater 2017, 51, 374-392. IF:6.4
10. Xia, Y.; Yuan, M.; Deng, Y.; Ke, X.; Ci, T. Different effects of silica added internal or external on in vitro dissolution of indomethacin hot-melt extrudates. Int J Pharm 2017, 534 (1-2), 272-278. IF:3.9
